Digestible lysine effects on gene expression by Japanese quails in the pre-laying phase

This study aimed to determine the effects of digestible lysine levels in the diets of Japanese quail (Coturnix coturnix japonica) on performance, blood parameters and the expression of insulin-like growth factor I, and growth hormone receptor (GHR), apolipoprotein A-I (APOA-I), acetyl-CoA-carboxylase (ACC), and fatty acid synthase (FAS) genes. A total of 288 seven-day-old female Japanese quails were randomly assigned to one of three diets that contained 0.8%, 1.10%, or 1.40% digestible lysine. The birds were slaughtered at 42 days old, and relative gene expression was evaluated in the liver by qRT-PCR using the 2-ΔCT method. Lysine supplementation had no effect on weight gain and feed conversion. Abdominal fat was lower in birds supplemented with 0.8% digestible lysine than those supplemented with 1.10% and 1.40%. Increased total cholesterol and triglycerides were elevated in quails that received supplementation of 1.10% digestible lysine compared with the other diets. High density lipoproteins were decreased in birds that received 0.8% digestible lysine. Quails fed with 1.40% digestible lysine had greater expression of GHR and APOA-I than quails fed diets with 0.8 and 1.10% (P <0.05). The greatest expressions of ACC and FAS were observed in the liver of quails fed with 0.8% digestible lysine. The current results suggest that lysine supplementation in the pre-laying phase allows birds to deposit muscle mass to reach the optimal conformation and body fatness that provides an energetic reserve for the productive phase by modulating the expression of genes related to growth and lipid metabolism. Keywords: Coturnix coturnix japonica, growth, growth hormone, lipid synthesis, lipid metabolis

Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry.

BACKGROUND: The Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF) is an ongoing prospective noninterventional registry, which is providing important information on the baseline characteristics, treatment patterns, and 1-year outcomes in patients with newly diagnosed non-valvular atrial fibrillation (NVAF). This report describes data from Indian patients recruited in this registry. METHODS AND RESULTS: A total of 52,014 patients with newly diagnosed AF were enrolled globally; of these, 1388 patients were recruited from 26 sites within India (2012-2016). In India, the mean age was 65.8 years at diagnosis of NVAF. Hypertension was the most prevalent risk factor for AF, present in 68.5% of patients from India and in 76.3% of patients globally (P < 0.001). Diabetes and coronary artery disease (CAD) were prevalent in 36.2% and 28.1% of patients as compared with global prevalence of 22.2% and 21.6%, respectively (P < 0.001 for both). Antiplatelet therapy was the most common antithrombotic treatment in India. With increasing stroke risk, however, patients were more likely to receive oral anticoagulant therapy [mainly vitamin K antagonist (VKA)], but average international normalized ratio (INR) was lower among Indian patients [median INR value 1.6 (interquartile range {IQR}: 1.3-2.3) versus 2.3 (IQR 1.8-2.8) (P < 0.001)]. Compared with other countries, patients from India had markedly higher rates of all-cause mortality [7.68 per 100 person-years (95% confidence interval 6.32-9.35) vs 4.34 (4.16-4.53), P < 0.0001], while rates of stroke/systemic embolism and major bleeding were lower after 1 year of follow-up. CONCLUSION: Compared to previously published registries from India, the GARFIELD-AF registry describes clinical profiles and outcomes in Indian patients with AF of a different etiology. The registry data show that compared to the rest of the world, Indian AF patients are younger in age and have more diabetes and CAD. Patients with a higher stroke risk are more likely to receive anticoagulation therapy with VKA but are underdosed compared with the global average in the GARFIELD-AF. CLINICAL TRIAL REGISTRATION-URL: http://www.clinicaltrials.gov. Unique identifier: NCT01090362

Software performance of the ATLAS track reconstruction for LHC run 3

Charged particle reconstruction in the presence of many simultaneous proton–proton (pp) collisions in the LHC is a challenging task for the ATLAS experiment’s reconstruction software due to the combinatorial complexity. This paper describes the major changes made to adapt the software to reconstruct high-activity collisions with an average of 50 or more simultaneous pp interactions per bunch crossing (pileup) promptly using the available computing resources. The performance of the key components of the track reconstruction chain and its dependence on pile-up are evaluated, and the improvement achieved compared to the previous software version is quantified. For events with an average of 60 pp collisions per bunch crossing, the updated track reconstruction is twice as fast as the previous version, without significant reduction in reconstruction efficiency and while reducing the rate of combinatorial fake tracks by more than a factor two